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ABSTRACT
BACKGROUNDExternal reference pricing (ERP), a frequently implemented pricing policy, seeks to rationalize prices and contain costs by using foreign prices as reference for the determination of domestic prices and facilitation of negotiation. Its use across 
countries	varies	significantly	in	terms	of	objectives,	methods, administration and implementation.
METHODA systematic literature review was conducted according to CRD guidelines. 17 Study endpoints were used to identify characteristics of ERP implementation across 29 countries, of which 17 were EU member states. Multiple databases were examined to provide a wide range of ERP sources. 
After	 filtering	 for	 mention	 of	 ERP	 implementation	related to at least one of the 17 study endpoints 176 studies remained. Primary data collection, in the form of questionnaires directed at key stakeholders, were also used to supplement data in instances where information received from the systematic literature review was outdated or minimal. Findings from the systematic literature review and primary evidence from key stakeholders were benchmarked against 14 best practice principles inherent to an optimal ERP system to determine the quality of ERP systems implemented by the countries of interest.
RESULTS
The	 systematic	 literature	 review	 confirmed	 that	there is heterogeneity in the way that ERP is implemented across countries. There tends to be variation in the size of the country baskets, with larger baskets becoming more common and in the way that countries chose their basket countries – some choose those with similar socioeconomic characteristics whilst others do not. Furthermore there is variation in the calculation used with most countries vying away from the average-based calculations towards the lowest basket price or the average of the lowest ‘n’ prices. The frequency of price revisions differs according to authorities and government negotiations, as does the rate at which 
exchange	rate	fluctuations	are	taken	into	account	in	pricing decisions. In terms of the 14 best practice principles Belgium, France, and South Africa adhered to the most principles whilst Bulgaria, Hungary and Romania had the most instances of non-adherence.
CONCLUSIONHeterogeneity and recent trends in ERP design have policy implications for governments, which include globally declining pharmaceutical prices and other, potentially more undesirable consequences such as launch delays in low-income countries, parallel trade 
reducing	 drug	 stock	 levels,	 inflated	 prices	 in	 low-income countries, reduced incentive for continued R&D and reduced access to medicines in some regions. Overcoming this issue to ensure that ERP 
is	beneficial	 to	all	 stakeholders	will	 require	a	 focus	on developing sustainable, transparent, simple and stable systems using a set of key guidelines that 
should	maximise	the	benefits	of	the	pricing	policy.
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EXECUTIVE SUMMARYThis paper aimed to highlight differences in the way that 29 countries implement ERP, which aims to contain medicine costs, using a systematic literature review-based process combined with primary evidence from key stakeholders. Of the 29 countries analyzed 17 were European Member States, with the remainder representative of Latin America, South East Asia, the Middle East and North Africa. Secondary data was collected from literature published between 2000 and 2015 on a set of 17 criteria (endpoints) based on the ERP system design. Databases examined included Web of Science (WoS), CINAHL, EconLit, Medline, ProQuest, Cochrane 
Library	and	Scopus.	Special	keywords	and	a	defined	search strategy were used to arrive at an initial 
list	 of	 studies.	 After	 filtering	 for	 mention	 of	 ERP	implementation related to at least one of the 17 study endpoints 176 studies remained. Primary evidence was collected via questionnaires distributed among key stakeholders. Results of the systematic literature review and of the primary evidence collection were contrasted with analysis of the goals and observed impacts of the different ERP systems to identify optimal design features of ERP systems.
Findings	 confirmed	 high	 levels	 of	 heterogeneity	between the ERP systems of different countries. Variation was present in many of the 17 endpoints analyzed. For example, some countries use ERP for all medicines, regardless of their patent status, whilst others use it only for in-patent medicines. ERP processes range from formal to informal and from the main to the supportive pricing policy in place in a country. In cases where the process is informal there 
is	 limited	 definition	 of	 policy	 objective	 and	 scope	which can affect transparency. Country baskets range in size from three to 36 (not including those countries that use prices in the medicine country of origin) whilst very few countries use any kind of wealth adjustment, even if countries are not selected based 
on	 financial	 characteristics.	 Reference	 calculations	tend to be based on a lowest price in the basket style calculation, rather than an average based calculation. Some countries use ex-factory prices, which do not 
reflect	confidential	discounts	or	rebates,	to	form	the	basis of their calculations meaning referenced prices 
do	not	reflect	reality.
Rapidly evolving healthcare costs and increases in life expectancy and chronic disease prevalence mean that reduced drug prices are the ultimate aim for most country governments. However, badly designed ERP systems can be detrimental to all stakeholders and should be avoided at all costs. ERP systems should be designed with both health and industrial policy aims in mind to ensure that the requirements of all stakeholders including patients, manufacturers and governments are represented in order to ensure that patients get access to well-priced medicines as and when required, governments can spend within their means and manufacturers have enough incentive to 
continue	investing	in	future	R&D	in	order	to	benefit	future patient populations.There are a number of key criteria that can be adhered to that may ensure an ERP system is designed to 
benefit	 all	 stakeholders	 and	 remains	 transparent,	simple, stable and sustainable. These criteria are based on the selection of reference countries and prices; the use of exchange rates; the types of products for which ERP should be used; price revisions; and the derivation of target prices. Furthermore, as no two countries are identical any EPR system should outline the objective and scope of the ERP system 
and	ensure	it	reflects	the	overall	healthcare	system’s	values and objectives. It is also recommended that target prices should align with the expected value of the product, determined by using HTA or a similar mechanism. Encouraging countries to follow such guidelines could ensure that ERP systems do not alienate the innovative pharmaceutical company and ensure that they are incentivized to continue investing in global R&D which in the long run will maximize global population health. In this paper, 14 basic principles that an optimal ERP system should 
follow	 were	 benchmarked	 against	 the	 findings	from the systematic literature review and primary evidence from key stakeholders to determine the quality of ERP systems implemented by the countries of interest. Belgium, France, and South Africa adhered to the most principles whilst Bulgaria, Hungary and Romania had the most instances of non-adherence.
The Implementation of External Reference Pricing within and across Country Borders 9
L O N D O N  S C H O O L  O F  E C O N O M I C S  A N D  P O L I T I C A L  S C I E N C E
1. INTRODUCTIONERP, also known as external price referencing or international price comparison/ benchmarking, is a widely used pricing policy with high global research interest. It is introduced when governments decide to use foreign drug prices to regulate domestic prices (EFPIA, 2014; Danzon and Towse, 2003) and to impose price caps based on prices of similar drugs in other reference countries (Houy and Jelovac, 2014) 
with	 the	 official	 definition	 being:	 “the	 practice	 of	using drug prices in several countries to derive a benchmark or reference price for the purposes of setting or negotiating prices in countries” (WHO, 2013; EFPIA, 2014). The primary aim of the pricing mechanism is to control in-patent drug prices (Ruggeri and Nolte, 2013) via the containment of pharmaceutical prices and expenditure (Espin et al., 2010). The widespread use of ERP generally arises due to government cost control requirements. Authorities can use international comparisons to evaluate the fairness or appropriateness of the actual price related to comparative cases (OECD, 2008). 
Specifically,	drug	prices	in	other	countries	are	used	as a reference to determine a limit for the entry price of a drug or reimbursement price (Nguyen et al., 2015).
The	 implementation	 of	 ERP	 varies	 significantly	between countries in terms of the various rules followed by individual countries to calculate the 
final	product	price	(Espin	et	al.,	2014).	For	example,	an increase in the number of reference countries in a basket generally leads to further reductions in drug prices (BMI Research, 2010). Furthermore, the countries used in the basket can affect price variation. Financial performance of the country, pharmaceutical pricing systems, publication of actual versus negotiated or concealed prices, exact comparator products and disease burden of the potential reference country all need to be taken into account when choosing reference countries (WHO, 2015).Although ERP may have the potential to contribute to improved access and counteract affordability problems sometimes seen in lower-income countries, there are potential consequences. The 
most	 significant	 concern	 is	 related	 to	 the	 fact	 that	ERP could lead high-income countries to demand 
low	 prices	 creating	 resulting	 difficulties	 for	 low-income countries. ERP-related price leakages can 
trigger a manufacturer to set either a single price or narrow band of prices before launch is allowed. Such linking of low and high income markets can lead to prices converging at a higher level than would have been the case if markets had been separate. In low-income countries, this can lead to inappropriately high prices and reduced access for patients. In high-income countries, whilst in the short run imported 
lower	 prices	 may	 be	 beneficial,	 in	 the	 long	 run,	lower revenues can lead to reduced return on R&D investment and consequently fewer new medicines (Danzon and Towse, 2003). Furthermore, marketing authorization holders may prefer initially to promote their products to high-price countries rather than low-price countries so that these high prices are used as references in countries performing ERP (Vogler et al., 2015). At the same time, the accuracy of international comparisons may be distorted due to methodological issues and differences across countries in strength, formulation and pack sizes available (Timur and Picone, 2010). ERP assessment is considered complex compared to other pricing methods. The promotion of transparency around the use of ERP may improve the accountability of decision-making, which could reduce uncertainty for manufacturers and eliminate discrimination and corruption (Espin et al., 2014).There is a need to study the implementation of ERP with a focus on differences in implementation across countries. The present study will attempt, via a combination of primary and secondary evidence, to contribute to the review, analysis and body of information about ERP structure and its alignment with other policies across countries where the following countries are of interest: Austria, Belgium, Bulgaria, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Turkey, Brazil, Egypt, Jordan, Kuwait, Lebanon, Qatar, Saudi Arabia, South Africa, South Korea and United Arab Emirates. To determine the quality of ERP systems implemented by the countries of interest we 
benchmark	 findings	 from	 the	 systematic	 literature	review and primary evidence from key stakeholders against 14 basic principles that an optimal ERP system should follow (Sullivan et al., 2017).
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2. METHODSBoth primary and secondary evidence have been used to identify characteristics of ERP implementation across 29 countries and to inform the discussion and analysis in the sections that follow. Secondary evidence was collected via a systematic literature review, which was carried out based on the CRD guidelines for systematic reviews.
2.1 STUDY ENDPOINTS
A	 number	 of	 defined	 endpoints	 relating	 to	 the	structural elements of ERP were analysed in this systematic literature review (see Table 1). The main role of ERP in each country of interest was analysed in order to determine differences in application across countries. Transparency was evaluated to examine fairness in pricing. We also investigated the role of stakeholders in the design of ERP systems and their involvement in any appeals processes. 
The number of basket countries and the criteria used for their selection was also analysed alongside the methods used for price calculation. The role of the patent status and innovation was taken into account. Furthermore, investigation around the inclusion of wealth adjustments, price revisions 
and	exchange	rate	fluctuations	was	necessary	given	their impact on price determination (Toumi et al., 2014). The sources, dissemination and accessibility of price data were also assessed as key issues in price setting. As far as interaction with other policies is concerned, the alignment of the pricing process with the reimbursement process was examined and the combination of ERP with different negotiation tools for reimbursement was used as an endpoint. The interaction of other pricing processes such as value based pricing (VBP) and health technology assessment (HTA) with ERP was also examined.
Table 1: Definition of endpoints in ERP implementation
Endpoints DefinitionStructural ElementsObjective and alignment with health system objectives Assesses the aim of international comparisons and the relationship with health systems’ objectivesCharacteristics of pharmaceuticals subject to ERP Takes into account the categories of drugs included in the ERP systemMain role Determine whether ERP provides the major or supportive role in negotiations and determination of drug pricesTransparency Includes the legislative criteria used by countries to promote a fair pricing processCompetent authorities in ERP implementation Presents the authorities in control of ERP policy implementation Appeals by stakeholders to regulator decisions Assesses the possible appeals of stakeholders in pricing process Number of basket countries and countries in the basket Presents the countries and the number of members included in each basketCriteria for basket country selection Assesses the appropriate criteria to select reference countries Type of comparator price Presents the selection of price category across countriesMethod for calculation of the reference price Examines the different methods of countries to determine reference priceSources of information for pricing decisions Presents the sources and stakeholders that contribute to public access of price dataInclusion of wealth adjustments Assesses whether wealth adjustments made to the reference price when countries of higher or lower GDP are included in the basket
Accounting	for	exchange	rate	fluctuations Assesses	whether	calculations	used	to	account	for	exchange	rate	fluctuations	across countriesInteraction with other policiesLink between price and reimbursement Refers to the countries that take into account price determination and reimbursement process at the same timeInteraction with HTA or VBP Assesses the parallel use of international comparisons with other methods to set drug pricesAlignment with other negotiation tools of reimbursement Refers to the combination of international comparisons with reimbursement purposes Link between ERP regulation and patent status Takes into consideration the role of patent status in ERP price calculation 
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2.2 SYSTEMATIC LITERATURE 
REVIEW: DATA SOURCES, SEARCH 
STRATEGY AND KEYWORDSBoth peer-reviewed and grey literature were examined to minimize bias and identify all relevant information. Multiple databases were utilised, these were the Web of Science (WoS), CINAHL, EconLit, Medline, ProQuest, Cochrane Library and Scopus. A combination of broad and policy key words were used to ensure that all relevant literature was captured. All synonyms and different phrasings of ERP or External Price Referencing were included in the search. The 
search	run	was	(“Pharmaceutical	Price	Regulation”	OR	
“Pharmaceutical	Regulation”	OR	 “Cost	Containment”	
OR	 “Pharmaceutical	 Pricing”	 OR	 “External	 Price	
Referencing”	 OR	 “External	 Price	 Referencing”	 OR	
“International	Price	Comparisons”	OR	“International	
Reference	 Pricing”	 OR	 “International	 Price	Referencing”) AND (drug OR drugs OR medicine OR medicines OR pharmaceutical OR pharmaceuticals). The search was restricted to keywords present within abstracts only, to limit the number of irrelevant papers being returned. When searching the WoS, the search terms were restricted to title only, as the option to restrict to abstract was not available. This study includes only papers in English. There were no restrictions in terms of country in the initial search to ensure that evidence is representative of a wide geographical range. However, once the search was concluded, the study was limited to the following countries: Austria, Belgium, Bulgaria, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Turkey, Brazil, Egypt, Jordan, Kuwait, Lebanon, Qatar, Saudi Arabia, South Africa, South Korea and United Arab Emirates. Our study included literature published from 2000 to 2016.We also completed a targeted and comprehensive search of the WHO, the WHO collaborating Centre for Pharmaceutical Pricing and Reimbursement policies and the OECD online databases to ensure that no valuable reports were excluded. The key words used 
to	 search	 these	 were	 “External	 Price	 Referencing”	
OR	 “External	 Price	 Referencing”	 OR	 “International	
Reference	 Pricing”	 OR	 “International	 Price	Referencing”. Relevant information was recorded and combined with the results of the systematic literature review. Finally, additional literature gathered from contacts was also included.
2.3 STUDY SELECTION, DATA 
EXTRACTION, EVALUATION AND 
SYNTHESIS
The	 results	 were	 filtered	 according	 to	 title	 and	abstract relevance to the topic. Papers with relevant titles were downloaded for further examination. In 
order	to	arrive	at	a	final	set	of	studies,	the	main	body	of these texts was assessed according to the following criterion: mention of ERP implementation relating to at least one of the selected endpoints. The number of studies based on evidence at each endpoint was noted with cases where some papers related to multiple endpoints, and were therefore referenced multiple times, being taken into account.An excel spreadsheet was used to extract the relevant information on each endpoint for the selected studies. It includes paper titles in the 
rows,	 endpoints	 in	 the	 columns	 and	 significant	information from the texts being extracted and entered into the respective cells. A comprehensive synthesis of the literature was carried out to identify key trends related to ERP implementation across countries. Results from other systematic literature reviews were included if the selected endpoints in the review were different to the respective 
endpoints	 in	 this	 study.	This	process	 is	 significant	in order to minimize bias of results.
2.4 PRIMARY DATA COLLECTIONAs evidence drawn from the systematic literature review was not conclusive, primary evidence was collected to complement the secondary evidence 
findings.	 Primary	 evidence	 was	 gathered	 via	questionnaires distributed to key stakeholders in all study countries, from which there were returns from 21 countries i.e.: Belgium, Bulgaria, Jordan, Qatar, Italy, Brazil, South Africa, Romania, Slovenia, Spain, Germany, Egypt, Latvia, Poland, Portugal, Russia, Hungary, Greece, France, Estonia and Slovakia. Respondents included representatives from government agencies, industry representatives and academics, all of whom expressed personal views on how ERP is implemented in their respective countries. Beyond understanding the characteristics of ERP in different settings, other important endpoints, such as the national and international effects of implementing ERP, were addressed in the questionnaires to increase understanding of how 
The Implementation of External Reference Pricing within and across Country Borders 12
L O N D O N  S C H O O L  O F  E C O N O M I C S  A N D  P O L I T I C A L  S C I E N C E
different ERP systems perform against 14 basic principles that each country should follow to achieve an optimal ERP system (see Appendix 1) (Sullivan et al. 2017). The questionnaire was divided into four 
sections	in	order	to	address	specific	thematic	areas	
around	ERP	and	its	use	within	specific	jurisdictions.	These areas were (i) Objectives and Scope of External Price Referencing Systems, (ii) Administration and Operations, (iii) Methods for the Conduct of External Price Referencing, and (iv) Implementation of External Price Referencing.
A combination of both primary and secondary evidence is presented in the results section. When evidence from the systematic literature review was 
used,	primary	data	were	used	to	validate	the	findings.	In cases where minimal or outdated evidence was drawn from the systematic literature review, primary data was used.Findings from both primary and secondary evidence were then benchmarked against a framework of 14 basic principles (Sullivan et al. 2017), which countries should follow in order to achieve an optimal ERP system (Appendix 1).
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3. RESULTS
3.1 RESULTS OF THE LITERATURE 
REVIEWThe database search yielded 6,877 studies and the results of the systematic literature search were combined with the results from the search of the WHO, the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement policies and the OECD online databases. Additional literature was provided by our network. 3,979 studies remained and were screened based on relevant titles and abstracts by removing the duplicates using EndNote software (see Figure 1). From the 3,979 studies, 3,526 were peer-reviewed papers and 453 were grey literature. 549 papers were then downloaded and assessed for eligibility. Many studies were excluded because they did not relate to ERP, others because they referred to internal reference pricing or because only the abstract was available, rather than the full text. The main body of 283 texts was then assessed. The detailed analysis of the studies providing evidence on each of the endpoints included can be seen in Table 
2.	176	papers	were	included	as	final	studies	in	this	
systematic	literature	review,	a	significant	proportion	of which were grey literature (138 studies) with only 38 peer-reviewed papers (Table 2). Throughout the text, the evidence shown in the tables refers to the latest available source.
3.2 OBJECTIVE OF ERP AND 
ALIGNMENT WITH HEALTH SYSTEM 
OBJECTIVESERP is a commonly implemented pricing policy, related to the use of prices of similar drugs to set and benchmark domestic prices (BMI Research, 2012). Generally, ERP has three main aims (Kanavos et al., 2010): (a) negotiate or set prices within a country, (b) negotiate coverage and reimbursement and (c) authorize product marketing. The use of ERP has 
increased	 significantly	 as	 a	 price	 control	 method	(Kanavos and Vandoros, 2011) in in-patent medicines and as a cost containment measure due to issues like 
the	global	financial	crash	in	2008,	the	increase	in	life	expectancy and the increase in prevalence of chronic conditions (Rémuzat et al., 2015).The general aim of ERP is the attainment of low domestic prices to limit pharmaceutical spend. For instance, Greece implemented price controls through 
ERP to limit pharmaceutical and budget spending (Economou, 2010), Turkey introduced ERP in order to control drug expenditure (BMI Research, 2016), Slovenia uses ERP as a tool to regulate the growth of public and private drug expenditure (Albrecht et al., 2009), and in 2010, Russia promoted ERP to regulate prices (Popovich et al., 2012). In Spain, ERP was implemented to control drug prices for which there are no alternatives available on the market (Rémuzat et., 2015); Latvia implements ERP to reimburse drugs at manufacturer prices (Behmane, 2007); and in Bulgaria, ERP aims to estimate a ceiling price for innovative and generic prescription drugs (Kazakov, 2007). In 2004, the Turkish government introduced ERP to contain pharmaceutical expenditure.However, complicated interrelations between countries can lead to issues around the achievement of these low prices (Barros et al. 2010) due to variations in the basket of reference countries, 
Figure 1: PRISMA flow diagram with search 
results from the systematic literature reviewAdditional records 
identified	through	other sources (n=143)
Final studies included (n=176)
Records excluded of irrelevance of title or abstract (n=3,430)
Number of articles assessed relative to the inclusion criteria (n=283)
Records	identified	through database searching (n=6,877)
Full text articles assessed for eligibility (n=549)
Articles excluded due to poor evidence (n=107)
Records screened (n=3,979)
Records after duplicates removed (n=3,979)
Full text articles excluded (n=266)
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the type of price compared, calculation methods 
employed,	 exchange	 rate	 fluctuations	 and	 data	availability (European Commission, 2015). Another paper in this series examines the impact of variations in ERP system design within- and across-countries on a number of different endpoints including pharmaceutical price levels, launch delays and price convergence (Kanavos et al., 2017)
3.3 CHARACTERISTICS OF PRODUCTS 
SUBJECT TO ERP PRICE REGULATIONThere are a number of variations in terms of the type of medicines subject to ERP systems. For example, the system can focus only on in-patent, originator drugs that are reimbursable (included in the national positive list), or, less commonly, on off-patent, generic drugs that are paid out of pocket. Generally the use of ERP is limited to originator products (Leopold et al. 2012, WHO 2015) but it can be applied to 
all marketed medicines, or particular categories of medicines such as reimbursable medicines, prescription-only medicines or innovative medicines (European Commission, 2015 and WHO 2015) (Table 3). According to the recommendations of EFPIA (2014), ERP should be limited to in-patent medicines because: (a) More dynamic and effective methods can enhance competitive prices in the off-patent market (b) Price comparison between in-patent and off-patent drugs undermines patent protection and intellectual property characteristics.Whilst there is some evidence describing the type of medicines covered by ERP policies in individual countries (see Table 3), ERP implementation mainly relates to reimbursable medicines (Vogler et al., 2008); Bulgaria, Romania, Slovenia and Poland set prices for generic prescribed drugs based on international reference pricing policy (Kazakov, 2007). Russia refers to retail prices of publicly 
Table 2: Results of systematic literature search by source
CINAHL Cochrane 
Library
Econ- 
Lit
Pro- 
Quest
Pub- 
Med
Scopus WoS OECD WHO WHO-
HiT
WHO 
CC-
PPRI
Net- 
work
No. of original studies 30 11 26 2,169 58 684 796 10 18 60 68 49
Peer-Reviewed 
studies
30 11 17 1,899 58 678 796 - - - - 37
Grey Literature - - 9 270 - 6 - 10 18 60 68 12No. of studies with relevant titles & abstracts 6 1 6 299 12 39 40 10 18 32 37 49
Peer-Reviewed 
studies
6 1 6 29 12 39 40 - - - - 37
Grey Literature - - - 270 - - - 10 18 32 37 12No. of studies that match endpoints 2 0 1 104 5 15 10 10 18 32 37 49
Peer-Reviewed 
studies
2 - - 11 4 15 10 - - - - 37
Grey Literature - - 1 93 1 - - 10 18 32 37 12No. of studies that match ERP Impact endpoints 2 0 0 87 2 6 7 8 2 15 27 19
Peer-Reviewed 
studies
2 - - 7 2 6 7 - - - - 14
Grey Literature - - 1 80 - - - 8 2 15 27 5
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Table 3: Type of pharmaceuticals subject to ERP across countries
Pharmaceuticals subject to ERP
 All medicines (regardless 
of inclusion in the 
national positive list)
Only medicines 
included in the 
national positive list
In-patent 
drugs only
All drugs 
regardless of 
patent statusAustria ü üBelgium ü üBulgaria ü üCzech Republic ü üEstonia ü üFrance ü üGermany ü üGreece ü üHungary ü üItaly ü üLatvia ü üPoland ü üPortugal ü üRomania ü üSlovakia ü üSlovenia ü üSpain ü üEgypt ü üJordan ü üKuwaitLebanon üUnited Arab Emirates ü üBrazil üRussia ü üSouth Korea üTurkey ü üSouth Africa ü
Sources: The authors, adapted from secondary and primary evidence
reimbursed medicines (Rudisill et al., 2014); Latvia, Poland and Austria use reimbursed drugs (Espin et al., 2014); and Portugal excluded hospital drugs from ERP, and Austria includes outpatient drugs in the ERP system (Rémuzat et al. 2014). Many countries 
do	not	specify	officially	whether	ERP	is	used	for	the	in-patent or off-patent market.
3.4 IS ERP THE MAIN PRICING POLICY 
OR A SUPPORTIVE TOOL?Our analysis showed that 29 EU countries implemented ERP as a major or supportive criterion in price determination (European Commission, 2015; Paris and Belloni, 2013; Mossialos et al., 2006), either formally or informally (OECD, 2008), 16 of them use 
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international comparisons as a core concept, while 
some	countries	 focus	on	specific	sectors	or	specific	medicines. The countries of interest are presented in Table 4 below.Russia seeks to inform pricing rules through ERP 
unofficially	(Rudisill	et	al.,	2014).	In	Belgium	ERP	is	used as a supplementary tool, although comparisons have resulted in price reductions in reimbursed 
patented	 drugs	 over	 the	 last	 five	 years	 (Toumi	 et	al., 2014). Germany introduced ERP to control reimbursement prices, while Italy changed the role of ERP from the major to a supplementary method 
to facilitate negotiations between industry and the Medicine Agency (Martini et al., 2012, Ferre et al., 2014). In Poland ERP serves only a complementary role to control the expenditure of the National Health Fund (Janiszewski and Bondaryk, 2007). In Slovenia ERP is the main policy used to determine maximum allowed prices, but it is also used in a supplementary role when prices are set at a particularly high or low level (European Commission, 2015).
3.5 TRANSPARENCY OF ERP PRICING 
POLICYAn ideal ERP system would be a transparent, administratively simple process requiring minimal information input (Kanavos et al., 2010) based on statutory pricing rules and regulations (Leopold et al., 2012). In reality ERP implementation contains a number of composite points which can be resource intensive and administratively complex, resulting in poor transparency. The level of transparency can be enhanced by specifying the basket of countries and improving the accessibility of pricing data sources used by countries for the referencing process. The estimation of medicine prices based on price caps or on the reference country average promotes predictability 
for	 industry,	 while	 flexible	 negotiations	 between	authorities and industry may lead to a less transparent procedure (OECD, 2008). Many low-income countries 
face	 difficulties	 in	 achieving	 transparency	 as	 they	lack a reliable historic and systematic data source on medicine prices (Nguyen et al., 2015). This can lead to ERP system distortion, as decisions will be based 
on	 virtual	 prices.	 It	 is	 difficult	 to	 find	 information	on the level of ERP system transparency in different countries but the systematic literature review completed here showed that countries like Austria, Portugal have highly transparent, well-established processes (Toumi et al., 2014) whilst countries like Estonia have reduced transparency (Table 5).
3.6 COMPETENT AUTHORITIES 
RESPONSIBLE FOR ERP 
IMPLEMENTATIONERP systems are implemented by different authorities across different countries. In some countries, ERP lies in the jurisdiction of the Ministry of Health and in others pricing committees or medicines associations are responsible for the process (see Table 6).
Table 4: Main Role of ERP
ERP as main (M) or supportive (S) methodAustria MBelgium SBulgaria SCzech Republic MEstonia SFrance SGermany SGreece MHungary SItaly SLatvia SPoland SPortugal MRomania MSlovakia MSlovenia MSpain SEgypt MJordan MKuwait MLebanon MQatar MSaudi Arabia MUnited Arab Emirates MBrazil SRussia SSouth Korea STurkey MSouth Africa M
Sources: The authors, adapted from secondary and primary evidence
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Table 5: Transparency in ERP across countries
Transparency in price settingAustria Well-established processBulgaria Lack of transparencyEstonia Insufficient	granularity	on	the	ERP	rulesFrance See note below1Germany Insufficient	granularity	on	the	ERP	rulesItaly Pricing	and	reimbursement	not	straightforward.	Conflict	between	government	and	industryPortugal Introduction of well-established pricing rules2Saudi Arabia Concern related to the weight of different factors in estimating pricesRussia Ministry	of	Health	and	Social	Development	of	Russia	provide	official	prices	for	drugs	to	consumers,	which	are	included on the essential medicines list.
Notes: 1In France, ERP is a part of an agreement between the Healthcare Products pricing committee and the pharmaceutical companies 
(Toumi	et	al.,	2014).	The	use	of	France	as	a	reference	country	led	authorities	and	industry	to	find	many	incentives	in	order	to	induce	
hidden	price	payback	rules.	As	a	result,	authorities	can	buy	medicines	at	a	reasonable	price	and	industry	can	benefit	from	participation	in a large market. Nevertheless, applied discounts can create a gap between the actual and nominal price, while the actual price is not public in France. 2Portugal	have	promoted	defined	rules	about	price	comparisons	in	case	of	non-availability	of	similar	drugs	in	the	reference countries. (Leopold et al., 2012).
Sources: The authors, adapted from secondary and primary evidence
Table 6: Competent authorities in ERP implementation across countries
AuthoritiesAustria The Pricing Committee of the Federal Ministry of Health and Women’s IssuesBelgium Ministry of Economic AffairsBulgaria National Council for Pricing and Reimbursement of Medicinal Products (NCPR)Czech Republic State Institute for Drug Control (SUKL)Estonia Ministry of HealthFrance Comité Economique des Produits de Sante (CEPS)Germany National Association of Statutory Health Insurance FundsGreece EOF and Pricing committee of MOHHungary National Health Insurance Fund Administration (OEP)Italy AIFALatvia State Medicines Pricing and Reimbursement Agency (SMPRA) under the Ministry of HealthPoland Ministry of HealthPortugal InfarmedRomania Ministry of HealthSlovakia Ministry of HealthSlovenia Medicines Agency – Public Agency of the Republic of Slovenia for MedicinalSpain Interministerial Committee for Pricing and Reimbursement (CIPM)Egypt Ministry of HealthJordan Jordan Food and Drug Administration (JFDA)Kuwait Ministry of HealthLebanon Ministry of HealthQatar Ministry of Health Saudi Arabia Saudi Food and Drug Authority (SFDA) United Arab Emirates Ministry of Health Brazil National Health Surveillance Agency (ANVISA)Russia Ministry of Health and Federal Antimonopoly ServiceSouth Korea The Health Insurance Review & Assessment Service (HIRA) and the National Health Insurance Service (NHIS)Turkey General Directorate of Pharmaceuticals and Pharmacies South Africa Pharmaceutical Economic Evaluations (PEE) Directorate
Sources: The authors, adapted from secondary and primary evidence
The Implementation of External Reference Pricing within and across Country Borders 18
L O N D O N  S C H O O L  O F  E C O N O M I C S  A N D  P O L I T I C A L  S C I E N C E
3.7 APPEALS BY STAKEHOLDERS TO 
REGULATOR DECISIONSThere is limited evidence on the presence of an appeals process for stakeholders. Information was only isolated in one country – the Czech Republic, where in June 2008 a newly implemented ERP system set maximum prices for 3,944 products. As a result, at the end of 2008, price cuts led to a number of appeals by industry due to distortion in price regulation (BMI Research, 2010).
3.8 NUMBER OF BASKET COUNTRIES
The	number	of	countries	in	a	basket,	and	the	specific	
countries	 chosen,	 can	 have	 a	 significant	 impact	 on	resulting drug prices (Houy and Jelovac, 2013) – a small number of reference countries could give 
significant	 weight	 to	 few	 countries	 whilst	 a	 large	
basket	 size	 can	 increase	 administrative	 difficulty	without adding any value.
EU members generally elect to use a reference basket that contains 5 to 20 countries (Ruggeri and Nolte, 2013). Table 8 (adapted from Kanavos et al. (2010) and Toumi et al. (2014)) highlights the size of country baskets in European countries and the number of times each country is used as a reference in the basket of another country. Italy currently selects drug prices by referencing the largest number of EU countries, while it is referenced by only a limited number of reference countries (Austria, Belgium, France, Germany, Greece, Portugal and Spain). In recent years there has been a trend to increase the basket size (Houy and Jelovac, 2014), potentially as a means to reduce medicine prices further.Austria expanded its basket of countries from 14 to 24 countries, while the Czech Republic used only 8 countries until 2009 (Leopold et al., 2012). In 2010, Greece increased its basket to 22 EU countries in order to reduce pharmaceutical prices and cut 
pharmaceutical	 expenditure	 due	 to	 the	 financial	crisis. Other countries have also increased or have expressed interest in increasing the number of reference countries they use: Slovakia (from 8 countries in 2009 to all EU members) and Latvia (which is carrying out negotiations for the expansion of the number of reference countries used).Germany, UK and France are the most referenced countries, because they launch drugs early and two of them (Germany, UK) employ free pricing methods for in-patent drugs (OECD, 2008).
3.8 FREQUENCY OF PRICE REVISIONSAlongside the number, and choice, of countries, in the basket the frequency of price revisions can affect the prices derived using ERP. Many EU countries have a legal framework that calls for price renewals on a regular basis with regular intervals lasting from three 
months	to	five	years	(Rémuzat	et	al.,	2015).	Frequent	price revisions may distort the role of the market, as they may reduce predictability and produce errors, especially when large baskets of countries are used (EFPIA, 2014). Nevertheless, the appropriate interval of price revisions depends on the respective national policy (European Commission, 2015) (See Table 10).
Table 7: Presence of appeals process for 
stakeholders
Presence of appeals process for stakeholders
Austria ü
Belgium ü
Bulgaria ü
Czech Republic ü
Estonia 
France 
Germany ü
Greece ü
Hungary 
Italy 
Latvia ü
Poland 
Portugal ü
Romania 
Slovakia ü
Slovenia ü
Spain ü
Egypt ü
Brazil ü
Russia 
Turkey ü
South Africa ü
Sources: The authors, adapted from secondary and primary evidence
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Table 8: Overview of baskets across countries
Notes: 1Belgium, the Czech Republic, Poland, Hungary, Denmark, Finland and Estonia are included as additional reference countries in case of non-availability of drug pricing data in other basket countries. 2The Czech Republic and Spain contribute as alternatives in case of non-availability of drug pricing data in other basket countries. 3Whilst Cyprus has an overall basket of 10 countries the actual price is based on a selection of countries from each of three sub baskets – high income (Denmark, Germany and Sweden); medium income (Austria, Belgium, France and Italy); and low income (Greece, Portugal and Spain).
Sources: The authors, adapted from secondary and primary evidence
3.9 CRITERIA FOR BASKET COUNTRY 
SELECTIONIn terms of basket content, countries mainly take into account the following components to create a 
basket:	(a)	geographical	characteristics,	(b)	financial	similarity (Vogler et al., 2011), (c) availability of price data, (d) public health status and health insurance and (e) investment and contribution of 
pharmaceutical	 industry	 in	 financial	 performance	(Critchley 2006).
There is limited information on the criteria that most countries use to choose their basket. Most EU countries use other EU members as references (OECD, 2008). For instance, the three Baltic countries (Estonia, Latvia and Lithuania) use each other in their reference baskets as they have common socioeconomics factors (Pudersell et al., 2007; Behmane et al., 2008), while northern and southern EU countries follow a similar trend (European Commission, 2015).
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Table 9: Number of reference countries in basket 
across other non-EU countries
Countries Number of reference 
countries of basketBrazil1 9Egypt 36 (and other optional)Jordan 16Kuwait Country of originLebanon 14Qatar Country of origin (and 2 optional)Saudi Arabia 30South Africa2 5South Korea 7United Arab Emirates3 31
Notes: 1Brazil includes the following countries in the basket: USA, Canada, Portugal, Spain, France, Italy, Greece, New Zealand and Australia. 2South Africa includes the following countries in the basket: Australia, New Zealand, Canada, Spain. 7Prices are set to innovative drugs based on the ex-factory prices in seven industrialized countries (BMI Research, 2012). 3Pricing is set at the median from referenced EU countries, the lowest price paid either in Saudi Arabia or the lowest price of an active pharmaceutical ingredient in the country of origin (BMI Research, 2015).
Sources: The authors, adapted from secondary and primary evidence
Table 10: Frequency of price revisions across the 
studied countries
Frequency of price revisionsAustria Two additional evaluations at six-month intervals, if reference prices were available in fewer than 12 EU Member States at the time of the initial evaluation; ad hoc revisionsBelgium At launch onlyBulgaria For reimbursed pharmaceuticals- every 6 months, For non-reimbursed- at launch onlyCzech Republic AnnuallyEstonia For outpatient: on the basis of price agreement duration; For inpatient: once, annuallyFrance Every 4 to 5 years at product re-assessmentGermany At launch only, at manufacturer’s request and if new evidence becomes availableGreece Biannual revision within four years of market entryHungary At launch onlyItaly Ad-hoc and periodically depending on 
specific	agreementsLatvia Every two yearsPoland Ad-hoc and periodically in tiered intervals 
(every	two,	three,	or	five	years)Portugal AnnuallyRomania AnnuallySlovakia Twice per yearSlovenia Twice per yearSpain Every two years and ad hocEgypt At launch, at manufacturer’s request and on a random basisJordan Every 2 years (plus four months after th reduction of prices in a reference country)Kuwait At launch onlyLebanon Every 5 yearsQatar At launch onlyBrazil At launch onlyRussia At manufacturers’ requestSouth Africa At manufacturers’ request
Sources: The authors, adapted from secondary and primary evidence
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Table 12: Price selection across countries
Type of comparator price usedAustria Ex-factory priceBelgium Ex-factory priceBulgaria Ex-factory priceCzech Republic Ex-factory priceEstonia Ex-factory priceFrance The starting point is the price claimed by the manufacturer; negotiation can use the ex-factory priceGermany Retail price (NB: ERP as guidance)Greece Ex-factory priceHungary Ex-factory priceItaly Ex-factory priceLatvia Ex-factory pricePoland Ex-factory pricePortugal Ex-factory priceRomania Ex-factory priceSlovakia Ex-factory priceSlovenia Ex-factory priceSpain Ex-factory priceEgypt Retail priceJordan Ex-factory priceLebanon Wholesale priceSaudi Arabia Ex-factory priceUnited Arab Emirates Wholesale priceBrazil Ex-factory priceRussia Wholesale and retail priceSouth Korea Ex-factory priceTurkey Ex-factory priceSouth Africa Ex-factory price
Sources: The authors, adapted from secondary and primary evidence
Table 11: Criteria for basket selection across 
studied countries
Criteria for basket selectionAustria All EU countriesBelgium Geographical proximity and comparable GDP levelsBulgaria Not	well	defined	criteria;	usually	countries	with similar GDP Czech Republic All EU countriesEstonia Geographical proximity and comparable GDP levelsFrance Geographical proximity and comparable GDP levelsGermany Geographical proximity and comparable GDP levelsGreece All EU countriesHungary Geographical proximityItaly ERP system is increasingly redundantLatvia Socioeconomic criteriaPoland All EU countriesPortugal The countries selected for the basket must have a similar per capita GDP to PortugalRomania No clear criteria are used to select basket countriesSlovakia Geographical proximitySlovenia Geographical proximitySpain Countries where the medicines are availableEgypt Geographical proximity, comparable GDP levels and the country of origin of the productLebanon The price of an imported drug is based on the cost in the country of originBrazil Countries	with	profile	similar	to	BrazilRussia Countries with similar GPD per capita level and consideration of the country of originSouth Korea South Korea does not specify the countries in the basket and decide on an ad-hoc basisTurkey Lowest in EU + geographical criteriaSouth Africa Countries where prices are accessible and are regulated. Quality standards of countries also need to be similar.
Sources: The authors, adapted from secondary and primary evidence
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Table 13: Method for calculation of reference 
price across countries
Method of calculation of reference priceAustria Average across basketBelgium Average across basketBulgaria Lowest price in basketCzech Republic Average of the three lowest prices in basketEstonia Price cannot exceed the highest price in the basketFrance “Prices	similar	to	reference	countries	and	not	lower than the lowest price”Germany Weighted based on market size and purchasing power parityGreece Average of the three lowest prices in basketHungary Lowest price in basketItaly Average across basketLatvia Third lowest price among Denmark, Czech Republic, Romania, Slovakia and HungaryPoland Lowest price in basketPortugal Follows different calculation methods depending on the sector. Outpatient: country average, Inpatient: lowest priceRomania Lowest price in basketSlovakia Average of the three lowest prices in basketSlovenia Lowest price in basketSpain Lowest price in basketEgypt Lowest price in basketJordan Average across basketLebanon The price of an imported drug is based on the cost in the country of origin. Final price needs to be lower than one of the following: (i) The ex-factory price in the country of origin. (ii) Import prices charged for the same brand in seven countries in the Middle East.(iii) The median manufacturers’ price in seven European countries, or (iv) The import price of similar drugs that are already marketed in Lebanon.Saudi Arabia Lowest price in basketUnited Arab Emirates Lowest price in basketBrazil Lowest price in basketRussia Lowest price in basketSouth Korea Average across basketTurkey Lowest price in basketSouth Africa Lowest price in basket
Sources: The authors, adapted from secondary and primary evidence
3.10 TYPE OF COMPARATOR PRICE 
USED IN ERPMost European countries have used ex-factory prices in their international comparisons (Kalo et al., 2015), because this method helps to minimize price deviations that may arise due to differences in distribution mark-ups (Nguyen et al, 2015). The implementation of ERP using the ex-factory price is considered to be more suitable than other methods, for example, using the wholesale price, as distribution margins and tax rates are different across countries 
leading	 to	 difficulties	 in	 international	 comparisons	(EFPIA, 2014). However, there are some countries that use the wholesale price and some that use the pharmacy retail price (Espin et al., 2014) (see Table 
12).	 ERP	 is	 generally	 based	 on	 officially	 published	prices. Since price negotiations and discounts are 
kept	 confidential	 within	 a	 country	 most	 countries	will be using reference prices that may be higher than the negotiated price enjoyed in the reference country.
3.11 METHODS FOR CALCULATION OF 
THE REFERENCE PRICEGenerally, the most preferred method of reference price calculation is the use of an average formula (Gandjour, 2013) although there are other mechanisms in use, such as using the average of the n lowest or the lowest price in the basket. (European Commission, 2015). In the countries studied in this paper using a lowest price based calculation is the most common (Table 13), against the recommendation of EFPIA (2014) which states that an average price be used to enhance fairness. According to our results, some countries may include more than one criterion to set the reference price of a product, while other members may not refer to the 
selected	method	officially.
3.12 SOURCES OF INFORMATION FOR 
PRICING DECISIONSThe implementation of ERP requires access to price information and according to EFPIA (2014), this data should be publicly available and reliable. Non-availability, price heterogeneity, non-reliability and a lack of transparency can reduce the effectiveness of ERP (Rémuzat et al., 2015). Many countries support free access to price data, although the extent that 
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Table 14: Sources of information across countries
Sources of information for pricing decisionsAustria ManufacturersBelgium Manufacturers and public information sources (e.g. websites)Bulgaria Access	to	confidential	pricing	information	–	EURIPIDCzech Republic Manufacturers and public information sources (e.g. websites)Estonia Manufacturers and public information sources 
(e.g.	websites)	and	access	to	confidential	pricing information France Public information sources (e.g. websites)Germany Manufacturers and public information sources (e.g. websites)Greece Manufacturers and public information sources 
(e.g.	websites)	and	access	to	confidential	pricing information Hungary Public information sources (e.g. websites) and 
access	to	confidential	pricing	information	Italy Manufacturers and public information sources (websites)Latvia ManufacturersPoland Manufacturers	and	access	to	confidential	pricing information Portugal Manufacturers and public information sources (websites)Romania ManufacturersSlovakia Public information sources (e.g. websites)Slovenia Public	information	&	confidential	sources	(websites)Spain Access	to	confidential	pricing	information	Egypt Manufacturers and public information sources 
(e.g.	websites)	and	access	to	confidential	pricing information Jordan ManufacturersLebanon Manufacturers and public information sources (e.g. websites)United Arab Emirates Manufacturers and public information sources (e.g. websites)Brazil Currently price database via UNASUR in the mediaRussia Manufacturers and public information sources 
(e.g.	websites)	and	access	to	confidential	pricing information Turkey National Authorities of reference countries (public info)South Africa Manufacturers and public information sources 
(e.g.	websites)	and	access	to	confidential	pricing information 
Sources: The authors, adapted from secondary and primary evidence
different stakeholders contribute to the accessibility of information varies across countries (see Table 14). Generally, in EU countries the necessary price data is provided by the marketing authorization holder (i.e. the manufacturer) (European Commission, 2015).
3.13 INCLUSION OF WEALTH 
ADJUSTMENTS IN ERP CALCULATIONSWhilst most countries reference those with similar economic criteria there are situations where countries reference those with a higher GDP – for example Bulgaria, with a GDP of $7929 (per capita) referencing France, Spain and Italy (European Commission 2015). In such situations, countries can account for differences in GDP by making wealth adjustments based on Purchasing Power Parity (PPP) or GDP growth. Despite this possibility, evidence shows that none of the studied countries perform such adjustments meaning that countries referencing those with higher GDP than themselves 
may	 be	 exposed	 to	 artificially	 high	 prices	 and	 vice	versa. Germany reports that a formal weighting of prices by the estimated yearly turnover of a pharmaceutical and PPP of other countries could be applied, although whether or not this has ever been implemented is unknown.
3.14 ACCOUNTING FOR EXCHANGE 
RATE FLUCTUATIONSSimilarly, if countries reference those with different 
currencies	 then	 exchange	 rate	 fluctuations	 can	
influence	 the	 calculated	 reference	 price	 (Kanavos	et al., 2010). If weaker currencies and / or poorer countries are used in the reference basket, a downward adjustment is usually seen as exchange rates are used to contain prices. In Estonia, valid exchange rates are taken into account in the price calculation (Pudersell et al., 2007). In the Czech Republic, price estimation is based on the average exchange rates for the three months prior to the review (BMI Research, 2010) and in Jordan, exchange rates are taken into account due to possible price changes (BMI Research, 2015). In Turkey, which references EU countries using the Euro, reference prices are converted to 70% of the previous year’s average exchange rate between the euro and the Turkish lira (BMI Research, 2016). In contrast Saudi Arabia is one of many countries that does not 
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Table 16: Methods for dealing with exchange rate 
fluctuations
Methods for dealing with exchange rate 
fluctuationsBulgaria ü(Fixed exchange rate)Czech Republic ü(Average exchange rates for the three months prior to the review)Estonia ü(Spot exchange rate)France ü(Use simple currency countries)Germany ü(Prices based on PPP provided by Eurostat)Greece ü(Spot exchange rate)Hungary ü(Moving average of previous 3 months)Latvia ü(Moving average of previous 60 days)Poland ü(Monthly average rate of the Polish National Bank for the month prior to submission)Romania ü(Quest III methodology is used to establish the RON – Euro exchange rate) Slovakia ü(Moving average of previous 12 months)Spain ü(Fixed exchange rate)Egypt ü(Use the exchange rate at the time when the pricing decision is made)Jordan ü(Use moving average of the previous month)Brazil ü(Moving average of previous 60 days)Russia ü(Spot exchange rate)Turkey ü(Reference prices will be converted at 70% of the previous year’s average exchange rate between the euro and the Turkish lira)South Africa ü(Moving average of previous years)
Sources: The authors, adapted from secondary and primary evidence
Table 15: Inclusion of wealth adjustments in ERP 
calculation
Inclusion of wealth adjustmentsAustria Belgium Bulgaria Czech Republic Estonia France Germany Greece Hungary Italy Latvia Poland Portugal Romania Slovakia Slovenia Used to be (85% of ERP)Spain Indirectly through Eurozone basketEgypt Jordan Kuwait Lebanon Qatar Saudi Arabia United Arab Emirates Brazil Russia South Korea Turkey 
Sources: The authors, adapted from secondary and primary evidence
consider exchange rates in price determination (BMI Research, 2016). Some countries in the Eurozone, notably Spain, have moved to using Euro only countries in their reference basket to avoid multiple currencies and decrease price parities.
3.15 LINK BETWEEN PRICE AND 
REIMBURSEMENTERP can be aligned with the reimbursement processes to contribute to price reduction (Kanavos et al., 2010) (Table 17). Concerns arise from the determination of reimbursement prices using ERP. 
These	concerns	centre	around	the	“appropriateness”	of chosen reference countries (for example, countries with higher levels of GDP or bigger markets), 
and	 the	 confidentiality	 of	 negotiated	 prices	 in	the reference countries (BMI Research, 2016). In Slovenia the introduction of ERP is an additional tool to improve the drug reimbursement system (Albreht et al., 2009). In 2011, Slovakia introduced pharmacoeconomic analysis of publicly reimbursed drugs to control pharmaceutical expenditure in parallel to international price comparisons (BMI Research, 2012).
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3.16 INTERACTION OF ERP WITH HTA 
AND VBPERP implementation can limit the ability of other methods to regulate drug pricing (Koh et al., 2016) and any combination of approaches can present 
difficulties	 when	 determining	 the	 most	 effective	pricing policy. ERP does not take into account the role of VBP, which is related to the contribution of drugs to patients’ health and society (EFPIA, 2014). This is because ERP is often thought of as a more technical and administratively complex process than VBP, due to the requirements of large amounts of price data (Vogler et al., 2014). In addition, the value of drugs, which is considered under VBP, can differ across countries (Paris and Belloni, 2013). The alignment of the two methods is complex as price determination should be based on value, which is subject to various assessments (Toumi et al., 2014).As far as price setting based on HTA recommendations 
is	concerned,	its	inefficient	implementation	may	lead	to ERP use, ultimately aiming to contribute to drug 
spending	 control.	The	 final	 assessment	of	HTA	and	the outcomes of cost-effectiveness analysis (which 
are	supposed	to	reflect	willingness	to	pay	of	society)	may not be taken into account due to the parallel use of international comparisons (Koh et al., 2016).
3.17 ERP ALIGNMENT WITH 
OTHER NEGOTIATION TOOLS OF 
REIMBURSEMENTThe use of ERP can facilitate the negotiation and reimbursement processes (WHO, 2015). It is generally seen as one of the criteria used in price negotiations, with other factors including issues such as R&D expenditure (Gandjour, 2013). In Italy and Estonia, pricing negotiations and the reimbursement process are based on a combination of ERP and internal reference pricing (Martini et al., 2007; Pudersell et al., 2007). In France and Spain, 
ERP	operates	as	a	significant	method	in	negotiations	
between authorities and industry for innovative drugs of high therapeutic value (Ruggeri and Nolte, 2013) (Table 17).In the Czech Republic, EU prices and the following criteria are evaluated for negotiation 
and	 reimbursement	 purposes:	 clinical	 efficacy,	reference prices, budget impact and a form of cost-effectiveness analysis (Kanavos et al., 2010). Countries and health authorities may apply some informal evaluation methods for reimbursement, while other governments can use different ERP designs to enhance negotiations with the in-patent drug industry (Europe Economics, 2013; Espin et al., 2014).
3.18 LINK BETWEEN ERP 
REGULATION AND PATENT STATUSCountries should take into account the value of innovation in ERP design. Drug authorization and patent-expiry vary across countries and thus the same product can be in-patent in one country and off-patent in another at the same time. In most cases, when a drug loses patent protection the price is reduced compared to its in-patent price. Therefore, it is possible that a country where the drug is still in-patent is using reference prices from a country where the drug has lost its patent protection and is 
therefore	cheaper.	This	could	lead	to	artificially	low	prices in the referencing country which could lead to spillover effects such as parallel trade. Evidence in the literature on whether ERP respects the patent status is scarce to non-existent, however, it has been recorded that the Czech Republic does not take into consideration the patent protection status in the comparison of drugs (BMI Research, 2014) which 
was	 confirmed	 in	 the	 stakeholder	 questionnaires.	Estonia, Portugal, Slovakia, Egypt, Brazil and Russia have also been reported to take the cheaper or generic product price to inform their basket (Table 17).
The Implementation of External Reference Pricing within and across Country Borders 26
L O N D O N  S C H O O L  O F  E C O N O M I C S  A N D  P O L I T I C A L  S C I E N C E
Table 17: ERP relationship with other pricing and reimbursement policies
Link between 
price and 
reimbursement
Interactions between ERP and 
HTA/VBP
Alignment with other 
reimbursement & 
negotiation tools
Link between ERP and 
patent status
Austria ü Results of HTA are not systematically incorporated into public decision-making Despite ERP, there are financial	arrangements	with	manufacturers  Belgium  There is no interaction between HTA and ERP “Given	the	artificial	nature	of	the list prices, ERP is not useful to use in price negotiations.” ü- Takes the originator brand to inform our basketBulgaria ü HTA is performed before ERP setting. HTA serves as a basis for approval of the list price and reimbursement price.
No, but discount agreements for innovative drugs are contracted annually ü- Takes the originator brand to inform our basket
Czech Republic ü Pricing: ERP; Reimbursement: ERP with other criteria, incl. HTA ERP as a negotiation tool for innovative drugs - Takes the cheaper product/generic product to inform our basketEstonia ü ERP and HTA are not directly linked. When the price is calculated based on the HTA, the price is compared with prices within the basket and cannot exceed the highest one.
ERP is one tool for setting a fair price of a pharmaceutical. However cost-effective price, internal reference price and RSA have a bigger impact during the negation process. 
- Takes the cheaper product/generic product to inform our basket
France ü Interaction between HTA and ERP during the negotiation process of pharmaceuticals with an ASMR I-III. ERP as a negotiation tool for innovative drugs ü- Takes the originator brand to inform our basketGermany ü Both information from HTA and ERP are used to inform the price negotiation process (if there is added value of the new product)
ERP as guidance for price negotiation if needed  
Greece ü Critical for pricing/reimbursement; used with clawbacks/rebates “ERP	reflects	the	maximum	price that the system could reimburse, adjusted downwards by rebates and discounts.”
 
Hungary ü There is no link between HTA and ERP. The ERP originated from HTA cannot be higher than the lowest price in Europe.
“First	criteria	of	negotiation	is to be in line with the legal regulation of ERP-requirements. All the other tools can be used afterward.”
ü- Takes the originator brand to inform our basket
Italy ü The role of ERP is marginal in the Italian setting; used as a criterion to guide negotiations ERP and Internal Reference Pricing  Latvia ü Pricing: ERP: Reimbursement: other criteria, incl. HTA  Poland (ü) The price negotiations are carried out after the HTA process “Price	comparison	used	a	negotiation tool particularly when lower prices are available in more wealthy countries”
 
Portugal ü ERP	is	used	to	fix	ex-M	price	of	outpatient medicines; For inpatient, ERP is used in the negotiation process along with the HTA decision
HTA process is followed by negotiation and results in 
financial	RSA

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Link between 
price and 
reimbursement
Interactions between ERP and 
HTA/VBP
Alignment with other 
reimbursement & 
negotiation tools
Link between ERP and 
patent status
Romania ü ERP	can	influence	the	estimated	budget impact of a new reimbursed drug, which is one of the criteria considered in the Romanian HTA scorecard; critical for pricing/reimbursement
Negotiation takes places at Insurance House level & is combined with RSAs; as of end-2016, there were only a handful of RSAs
ü- Takes the originator brand to inform our basket
Slovakia ü HTA mandatory requirement since 2011 (CEA/CMA plus BIA) “For	some	highly	innovative	medicines for which, there are no alternatives in the market, they can be reimbursed through PAS”
- Takes the cheaper product/generic product to inform our basket
Slovenia  Some HTA performed at basic level despite the initiatives put forward by the NIPHSpain ü ERP is used as another criterion for 
pricing,	jointly	with	efficacy	and	budget impact analysis ERP as a negotiation tool for innovative drugs ü- Takes the originator brand to inform our basketEgypt ü Critical for pricing/reimbursement “ERP	plays	a	major	role	in	the	negotiations to get an even lower price than lowest one” - Takes the cheaper product /generic product to inform our basketJordan Critical for pricing/reimbursement   Kuwait Critical for pricing/reimbursement   Lebanon Critical for pricing/reimbursement   Qatar Critical for pricing/reimbursement   Saudi Arabia Critical for pricing/reimbursement   United Arab Emirates Critical for pricing/reimbursement   Brazil ü List price via ERP is the starting point for discounts for the public system, SUS. Negotiation between HTA Committee (CONITEC) and companies reduces the ERP prices
“As	explained	to	SUS,	discounts	applied to the public system after ERP.” - Takes the cheaper product /generic product to inform our basket
Russia ü N/A  - Takes the cheaper product /generic product to inform our basketSouth Korea HIRA uses economic evaluation to influence	the	pricing	of	drugs	and	medical devices, the formulary 
listing	and	the	benefit	package
  
Turkey ü Critical for P&R; extensive discounting for reimbursement   South Africa The ERP process results in the 
final	list	price.	The decision to reimburse is taken independently.
N/A  ü- Takes the originator brand to inform our basket
Sources: The authors, adapted from secondary and primary evidence
Table 17 continued: ERP relationship with other pricing and reimbursement policies
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4. DISCUSSION & POLICY IMPLICATIONSThe objective of this paper was to analyse ERP implementation in different geographical jurisdictions and to determine levels of interaction between ERP and other pricing and/or reimbursement policies. A systematic literature review was conducted in order to record the variations in ERP implementation across a set of 
countries.	Specific	endpoints	were	set	to	capture	the	
major	ERP	salient	features.	The	findings	of	this	review	are discussed in this section. An additional paper in this series analyses the consequences that these variations may have within and across countries (Kanavos et al., 2017). Moreover, a set of policy options, which could be followed by governments in order to achieve a transparent, simple, stable and sustainable ERP system, are presented.According to the systematic literature review all 29 countries of interest in this report have, at one point or another, implemented ERP, either as a major or supportive pricing process, to set or inform pharmaceutical prices.ERP has been widely used across our sample as a cost-containment tool as well as a price control method. For instance, Greece, Slovenia and Turkey introduced ERP to reduce and control drug expenditure, while Russia, Latvia, Bulgaria and Spain promoted international comparisons to regulate prices and attain lower level of prices.In several countries including Hungary and Italy, ERP is not only implemented in the pricing decision, but it is also aligned with the reimbursement process to contribute to further price reductions.Reimbursable and in-patent drugs are predominantly subject to ERP in order to control reimbursement prices. However, evidence from the systematic literature review shows that numerous countries such as Austria, Bulgaria, Jordan, Portugal and many others, use ERP in products regardless of their patent status whilst Belgium, Jordan and Romania use ERP for all medicines, regardless of their inclusion on the national positive list and resulting reimbursement.The majority of countries use ERP as their main pricing method with implementation taking a formal or informal role. 16 of the studied countries (including the Czech Republic, Slovenia and Greece) use international comparisons as a core pharmaceutical pricing method, while others 
(i.e.	 Germany)	 use	 ERP	 in	 specific	 medicines	 (i.e.	vaccines). When ERP implementation is informal, as in Italy and Russia, foreign prices may be used 
unofficially	 either	 to	 set	 prices	 of	 pharmaceuticals	or facilitate the negotiations between the competent authority and drug manufacturers. As a result, many 
countries	do	not	explicitly	define	 the	role	 that	ERP	plays in their pricing mechanisms.The transparency of ERP processes also varies between countries. Many countries, including 
Austria,	Portugal	and	Russia,	have	defined	legislative	and well-established frameworks, while others – Bulgaria and Italy – present less straightforward, less transparent processes. Variations have further been observed in the authority responsible for the implementation of ERP. In a few countries, such as Lebanon, Russia, Slovakia and UAE, ERP lies in the jurisdiction of the Ministry of Health. While, in the majority of the studied countries, ERP is implemented by pricing committees or medicines associations.
Significant	 heterogeneity	 across	 our	 sample	 was	observed in the number of the countries and the countries included in the ERP basket. According to the latest available data, ten countries out of the 29 of interest here have a large basket of 20 or more 
reference	 countries.	 Only	 five	 countries	 (the	 Czech	Republic, Spain, Romania, Jordan and Lebanon) out of the 29 have a medium-sized basket of 12-17 reference countries. 12 countries across our sample have a small basket of up to ten reference countries. Despite the majority of countries using a small basket there has been a recent trend to increase the size of the basket. Examples of this trend were drawn from Austria, the Czech Republic, Greece, Latvia and Slovakia.
Reference	 country	 selection,	 generally	 influenced	
by	 financial	 and	 geographic	 characteristics,	 data	availability, public health status and the role of industry in the country in question, is a key component of an ERP system. Despite is importance there is limited data highlighting the reasons behind basket country choice, over and above information on Estonia, Latvia and Lithuania, which tend to include countries with common socioeconomics factors in the selection of their basket. Many Northern and Southern EU countries also follow a similar trend (European Commission, 2015). Based 
on	our	findings	Germany,	the	UK	and	France	are	the	
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most referenced countries among European and some non-EU countries.In the countries studied in this paper, using a lowest price based calculation is the most common method to calculate the reference price. According to the latest available literature, 16 of the countries use the lowest price in the basket to derive the ERP. The Czech Republic, Greece and Slovakia use the n lowest of the basket as an alternative to calculate their prices. Whereas, South Korea, Austria, Portugal and Belgium use the average price across the reference basket.Evidence on the frequency of price renewals across the studied countries, was limited and drawn from ten countries. Portugal and Romania revise their prices annually, whereas Jordan and Latvia revise it biannually.Despite the fact that the majority of countries reference the ex-factory price, there is evidence that shows that ex-factory prices do not incorporate 
any	 confidential	 discounts	 and	 rebates	 negotiated	between payers and manufactures. As a result, 
it	 is	 common	 for	 referenced	 prices	 to	 not	 reflect	
reality,	which	 can	 lead	 to	 artificially	 inflated	prices	in some countries. Similarly, countries tend not to account for dynamic changes in exchange rates or reference country wealth differences, based on GDP or PPP. Consequently, countries referencing those with higher GDP, such as Bulgaria, may be exposing 
themselves	 to	 artificially	high	prices,	 counteracting	the general objective of ERP systems.Whilst ERP can be used in isolation, it can also be used in combination with other processes, such as HTA or VBP. Evidence on the interactions of ERP with other pricing regulations such as HTA or VBP is limited within the studied literature. The incorporation of ERP with additional tools for negotiation and reimbursement can improve access to medicines over and above price cuts. Italy, Estonia, France, Spain and the Czech Republic are examples of countries where ERP serves as part of the negotiation process in the 
final	 pricing	 decision	 of	 pharmaceuticals.	 Finally,	evidence in the literature on whether ERP respects the patent status is scarce to non-existent, however, it has been recorded that the Czech Republic does not take into consideration the patent protection status when calculating the reference price using the 
basket. Estonia, Portugal, Slovakia, Egypt, Brazil and Russia have also been reported to take the cheaper or generic product price to inform their basket.Our results have highlighted substantial heterogeneity in the design of ERP systems between countries. Such variations may be the result of the different health system policy objectives in individual countries, differing health requirements, different working budgets, and different pricing policies. Differences in the perception of value of innovation and of the importance of R&D may also result in such variations in the ERP design.The disparities seen in ERP design across countries can translate into effects on the pricing system. ERP, if implemented without alignment with public 
policy	 objectives,	may	 influence	 the	 price	 levels	 of	
pharmaceuticals	 resulting	 in	 inflated	prices	 in	 low-income countries, jeopardizing their availability and affordability and leading to reduced incentives for continued R&D.
These	issues	are	the	result	of	“path	dependence”,	for	which ERP has been criticized, i.e. the features of the 
ERP	system	influence	the	overall	outcome	achieved	(Leopold et al. 2012, Kanavos et al. 2010 and Rémuzat et al. 2015). For instance regular price revisions can lead to greater short-term cost-containment, due to lower price levels in a country. The level of price reduction also depends on the countries selected for the basket and the price considered in the basket.In a simulation exercise by the European Commission in 2015, it was shown that more frequent price revisions resulted in higher healthcare savings. In this scenario, the European Commission tested the extent of the price reduction if all countries re-evaluated their prices every six months. This resulted in a decrease of about 6% on the average medicine price in all 28 European Countries (European Commission 2015). Frequent price revisions, combined with 
exchange	 rate	 fluctuations,	 can	 impact	 prices	 in	 a	downward manner, and result in higher savings.In addition, in Slovakia, ERP tended to result in higher prices relative to neighboring countries, with similar income levels, due to basket country selection. This is because the German price and the price of the originator country of the pharmaceutical are used to calculate the Slovakian reference price, Germany 
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tends to have relatively high ex-manufacturer prices and the country of manufacture tends to be a high-priced country, given the production costs. However, due to an ERP policy change in 2009, Slovakia lowered prices by calculating the reference price using the mean of the six lowest price countries within Europe (Kalo et al. 2008, Leopold et al. 2012).The way in which ERP is implemented in a country might have an additional impact on the availability of pharmaceuticals in that country. This is due to ERP policies, which are most likely to take place in highly regulated and/or small markets. Markets 
with	 flexibility	 on	 pricing,	 or	 markets	 that	 are	large in size, with higher GDP, increased public healthcare spending, a higher percentage of GDP on health expenditure and a higher price level of pharmaceuticals are less likely to suffer from reduced availability (Håkonsen et al. 2009; Espin et al. 2014). For example, out of 15 European countries, Germany, where pricing is not regulated at ex-factory level, had the highest pharmaceutical prices and availability (Leopold, Mantel et al. 2012). Other examples include Slovakia, where a change in its reference country basket to include all EU Member states resulted in companies disregarding the newly implemented prices or lobbying for exemptions of their products, leading to access delays (Leopold, Vogler et al. 2012).Over and above the impact of ERP design within a country discussed above, the policy can have cross-border spillover effects. These include price instability, launch delays, unwillingness of manufacturers to launch in low price countries and price convergence towards the international average. For example, the frequency of price revisions is an important driver of price change over time when applying ERP. Yearly systematic price revisions can lead to faster price reductions when compared to revisions taking place every three years. Thus, increasing the frequency of price revisions will contribute to decreasing the overall pharmaceutical prices which can cause price erosion (Toumi et al. 2014).Finally, ERP design determines whether price convergence results in higher or lower prices. Larger baskets, and an increase in basket size over time, are associated with some price convergence between 
European pharmaceutical prices (Leopold et al. 2012, BMI Germany 2011 and Houy and Jelovac, 2014). It has also been argued that ERP can lead to a downward price convergence in Europe when the lowest price in the country basket rather than the average price is used to calculate the reference price (Toumi et al. 2014).In general, whilst there is convergence towards the mean there is no evidence that this is upwards. Importantly, if countries implementing ERP use the lowest, or the average of the lowest, of the basket one can hypothesis that any convergence seen will appear to be downwards as the mean will also decline.
4.1 POLICY IMPLICATIONS
Our	systematic	literature	review	revealed	significant	heterogeneity in the ERP processes used in the countries of interest. There are a number of policy implications resulting from some of the potentially suboptimal practices included in certain ERP systems such as launch delays in low-income countries, parallel trade reducing drug stock levels, 
inflated	 prices	 in	 low-income	 countries,	 globally	declining pharmaceutical prices, reduced incentive for continued R&D and reduced access to medicines in some regions. During the design phase of ERP governments are likely to focus on the short-term 
financial	 gains	 that	 could	 be	 the	 result	 of	 a	 newly	
implemented	ERP	system	that	uses	a	“lowest	price	in	the basket” style calculation. However, such decisions could negatively impact healthcare systems in the 
long	 term.	 Whilst	 it	 may	 be	 difficult	 to	 please	 all	stakeholders a number of ideas have been presented for approaching the issue of heterogeneity in a non-partisan, systematic way (Sullivan et al, 2017). 
These	key	principles,	which	make	up	an	“ideal”	ERP	system, are presented below. They are organized into four sections. (i) Objectives and Scope of External Price Referencing Systems, (ii) Administration and Operations, (iii) Methods for the Conduct of External Price Referencing, and (iv) Implementation of External Price Referencing. We assessed the 29 countries of interest for their adherence to these best practice principles. A discussion around this assessment is given after a description of each principle:
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4.1.1 Objectives and scope of external price 
referencing system
External price referencing system objectives 
should be clear and align with country specific 
health system objectivesOutlining the objectives and scope is an important 
first	 step	 in	designing	an	ERP	system.	They	 should	be contained within a scoping document, should be legislated and routinely reassessed. Health system goals should also be considered so that the ERP system functions cohesively within the health system and does not focus too narrowly or short-term. Mechanisms should be developed for monitoring the ERP system in order to ensure that target prices are selected and used in accordance with the guiding objectives.
External price referencing systems should focus on 
in-patent products considered for the purposes of 
coverage, pricing and reimbursement decisionsWithout external controls, the relative lack of competitive forces for newly launched, in-patent pharmaceutical products can result in exorbitant prices. With this in mind, ERP is most appropriately applied to in-patent medications. Off-patent medications are naturally subject to greater competitive forces, which drive down prices. In addition, there are other mechanisms available for directly or indirectly regulating prices of off-patent medications, such as price capping or internal price referencing, the latter being used extensively to set a price ceiling on reimbursement.
Prices developed using ERP should not override 
conclusions of health technology assessment 
(HTA) or value-based pricing approachesSeveral countries utilize ERP as an adjunct to explicit methods of value assessment, such as formal cost-effectiveness analysis. In principle using multiple approaches should be encouraged. However, some approaches, such as HTA and value-based pricing systems, have a stronger theoretical underpinning, in that they directly consider the overall value of a pharmaceutical agent to a population in order to make coverage decisions and determine prices. By contrast, ERP systems rely on prices set in other countries, often using unknown pricing mechanisms and methodologies. Therefore, ERP-based prices should not override those developed via other more 
robust evidence-based approaches, if they disagree. 
Further,	 final	 prices	 should	 align	 with	 conclusions	regarding the value of the product to the population. Overall, countries might expect to pay more for 
products	 providing	 greater	 benefit,	 even	 if	 ERP	results contradict this.
4.1.2 Administration and operations
The ERP system should have administrative 
simplicity and transparencyEnsuring administrative simplicity and transparency is important for several reasons. First, systems with these characteristics are easier to manage, which means that fewer resources will be required in order to establish and maintain them. Second, these features allow all relevant stakeholders to anticipate pricing decisions. This is also important for suppliers of pharmaceuticals in terms of obtaining clarity in each market they operate in. Uncertainty surrounding pricing mechanisms may cause suppliers to delay or even prevent entry into certain countries. In addition, price negotiations will likely be more straightforward if all parties concerned clearly understand the country’s pricing mechanisms, especially if these prices are strictly enforced. When deviations from the typical pricing procedures occur, the rationale should be documented and made publicly available. Finally, simple, transparent systems are less prone to corruption and are easier to audit in order to 
promote	efficiency.
Stakeholders should participate in the design and 
review of the ERP systemStakeholders representing a wide variety of interests, including industry, patients, health care professionals and academic experts, should be consulted in the design of the ERP system. At a minimum, stakeholder feedback should be elicited on the scoping document or the draft legislation. Involving a variety of stakeholders can result in a system that best balances the needs and concerns of all groups involved. It can also lead to greater transparency and decreased uncertainty. Any changes made to the ERP system and scoping document should incorporate stakeholder recommendations, and periodic input from these groups should be requested, to ensure that the system remains relevant.
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Stakeholders should be able to appeal regulator 
decisionsRegulators should develop a process and provide opportunities for stakeholders to appeal pricing decisions made explicitly using ERP. Allowing for appeals is essential, given the inherent uncertainty in prices developed via ERP. For example, referenced 
prices	may	not	 reflect	actual	 transaction	prices,	and	referenced countries often use unknown methods of arriving at a given price. The appeals process may also illuminate issues with the ERP system’s design or management and will allow extenuating circumstances to be presented and considered. Appeals should be documented, the process should be straightforward, stakeholders must be aware of the requirements of 
the	process,	and	timelines	should	be	finite.
Reference countries should be selected based on 
similarities in economic status and health system 
objectivesSelecting reference countries with a similar economic status and health system objectives increases the likelihood of arriving at appropriate price levels, which align with other healthcare decisions made within the country. Demanding the same price in lower-priced markets as in higher income markets could cause innovative pharmaceuticals to become prohibitively expensive for developing countries. In addition, heavily referencing lower-income countries could lead pharmaceutical companies to delay launches in those countries. If lower-income countries reference prices in higher-income countries, where more sophisticated methods such as HTA are used for determining value and pricing, prices can be adjusted, for example, using purchasing power parity (PPP) exchange rates, or through a per capita income adjustment indicator.
International implications of ERP 
implementation should be consideredThe wide use of ERP often has a number of unintended consequences internationally, which may directly or indirectly affect members of the broader stakeholder community. Worldwide decreases in drug prices may lead to decreases in research and development of new products. The value of pharmaceutical innovation to the healthcare system should always 
be	 considered	 and	 reflected	 in	 drug	 prices	 which	will require systems to consider the international implications of their pricing policies.
4.1.3 Methods for the conduct of external 
price referencing
Publicly available ex-factory prices should form 
the basis of the ERP system
Ex-factory	 prices	 are	 most	 reflective	 of	 actual	transaction prices compared to other prices, such as the retail price, which incorporates additional costs, vary across countries (e.g. wholesaler costs, pharmacy service fees and taxes) and are subject to national regulatory practices. Using publicly available sources to locate price information is ideal because it encourages transparency, though this information is not always available for all countries. Manufacturers and audit systems should provide alternative sources of information, when prices are not publicly available. Countries should consider incorporating multiple mechanisms for setting 
target	prices	so	that	information	deficiencies	do	not	delay price negotiations, as well as set time limits for the pricing processes to be completed.
The mean of prices in reference countries should 
be usedCurrently, most ERP systems use the mean, median or minimum price of referenced countries when developing a national target price. Assuming that reference country selection is based on similar economic status and health system objectives, using the minimum price is generally not appropriate, since countries with the lowest prices may have unusual public health or economic circumstances, which could justify a lower price. Therefore, an average price rule should form the basis of ERP systems with the median being used if outliers are a concern. If prices are not available in all reference countries price setting should proceed based on available information. Including more countries in the reference basket increases the likelihood of selecting a reasonable price while ensuring information availability.
Patent status should be respectedWhen determining target prices for in-patent products, whose patents may have expired in one or more reference countries, referring to prices of off-patent medications within the reference countries should be avoided. Patents provide necessary intellectual property protections for pharmaceutical companies by rewarding past research and 
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development efforts while encouraging future investments. In addition, ignoring patent protections may lead companies to avoid launching in certain markets, which would decrease access in those regions.
ERP formula should avoid the impact of exchange 
rate volatilityExchange rates can vary dramatically over time, so using an exchange rate at a single time point may result in unstable or perverse price estimates. Employing techniques to decrease the impact of this volatility on the estimated price, such as using a moving average of the exchange rate, is suggested. Countries within the European Economic and Monetary Union (EMU) could also consider excluding non-euro currencies, which tend to be more volatile. Exchange rates do not completely adjust for the purchasing power of a given currency, which can vary even when referencing countries of a similar economic status. To address this issue, countries could consider using purchasing power parity (PPP) exchange rates or adjusting prices to per capita wealth levels in the actual country compared with its comparators.
4.1.4 Implementation of external price 
referencing
Price revisions should be kept to a minimum and 
should be carried out consistently to avoid the 
perception of opportunistic behaviorPrice revisions should occur on an infrequent but scheduled basis and the schedule should be made public to ensure transparency and fairness. Typically, price comparisons would take place at launch, and price revisions could take place perhaps once or twice annually in order to ensure stability and administrative simplicity. Such an approach decreases uncertainty, while assuring a level of stability and predictability. It also prevents regulators from strategically adjusting prices, dependent upon the launch schedules of particular pharmaceutical agents.
ERP-based prices should be aligned with other 
tools used when negotiating reimbursementMany countries utilize price setting through ERP as an adjunct to other methods of value determination and risk management. Therefore, ERPs relative 
importance	 in	 defining	 list	 prices	 varies.	 When	negotiating reimbursement, insurers sometimes enter into managed entry agreements, wherein they 
agree	with	a	manufacturer	 to	share	 in	 the	 financial	risk of introducing a new pharmaceutical agent into 
a	 given	 market.	 Such	 agreements	 are	 confidential	in nature and can a take a number of forms, such as price-volume agreements, coverage with evidence development or outcome guarantees. Countries entering into these arrangements will need to consider how the prices developed using ERP align with such agreements. Countries with value-based pricing systems should proceed with caution in their thinking about introducing ERP, since potential reference countries may not be establishing prices based on product value. Additionally, other pricing tools can facilitate the implementation of differential pricing and, consequently, improve patient access to in-patent medicines in lower income countries. In all cases where ERP is used alongside other methods of price and value determination, the relative importance of ERP in establishing prices should be critically considered.
4.2 COUNTRY ADHERENCE TO 14 
BEST PRACTICE PRINCIPLESUsing the latest evidence drawn from the systematic literature review and the results from primary data collection, we analysed the extent to which the 29 countries of interest followed the 14 best practice principles (See Table 18). None of the countries in question seemed to follow all 14 of the principles with most failing to use the mean price of the basket and an administratively simple and transparent system which involved stakeholder participation. Most countries use the lowest price in the basket, or the average of the lowest n prices, have large baskets, reducing administrative simplicity. Similarly, whilst external stakeholders may be consulted, their contribution to the actual decision making related to ERP is practically null, it is an administratively driven process that excludes active participation by stakeholders. Belgium, France, and South Africa adhered to the most principles whilst Bulgaria, Egypt, Hungary and Romania had the most instances of non-adherence. Most countries adhered to using ex-factory prices, aligning ERP systems with negotiation tools and keeping price revisions to the minimum.
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5. CONCLUSIONThis paper aimed to identify detailed evidence on the methods by which ERP is implemented in 29 countries using a systematic review process combined with a survey of key informants. Of these 29 countries, 17 were EU member states with the remainder representative of the Middle East, South America and the rest of the world.A set of 17 criteria (endpoints), divided into two 
groups	 –	 “structural	 elements”	 and	 “interaction	with other policies” – were used to collect data on ERP systems with countries benchmarked against 
these	 endpoints.	 Our	 findings	 showed	 that	 there	
is	 significant	 heterogeneity	 between	 countries	 in	terms of the design of their ERP systems. Subsequent analysis highlighted the fact that none of the countries in question adhered to the 14 best practice principles thought to form an ‘optimal’ ERP system. There are a number of policy implications arising from heterogeneity and suboptimal practices, particularly when countries focus on using lowest price calculations and high-income countries reference lower priced countries with no wealth adjustment. These practices could undermine any potential 
beneficial	 ERP	 effects	 for	 government	 payers	 such	as cost-containment and low pharmaceutical prices. Suboptimal practices can cause spillover effects such 
as	 launch	 delays	 in	 low-income	 countries,	 inflated	prices relative to GDP in some countries, globally declining pharmaceutical prices, reduced incentive for continued R&D and reduced access to medicines in some regions. This is in direct contrast to the aims of ERP.
Rapidly evolving healthcare costs and increases in life expectancy and chronic disease prevalence mean that reduced drug prices are the ultimate aim for most country governments. But, carelessly employed ERP, which could be detrimental to all stakeholders, should be avoided at all costs. ERP systems should be designed with both health and industrial policy aims in mind. Schemes have to represent the requirements of all stakeholders including patients, manufacturers and governments in order to ensure that patients get access to well-priced medicines as and when required, governments can spend within their means and manufacturers have enough incentive to 
continue	investing	in	future	R&D	in	order	to	benefit	future patient populations. Developing such a system will require input from all actors during the design and review of ERP systems.Results from this paper, as well as the alternative paper in this series on the impact of different ERP systems, have shown that heterogeneity and suboptimal ERP practices can have detrimental effects for all stakeholders. Overcoming such issues in a non-partisan, systematic way can be achieved using the set of 14 best practice principles discussed here. By following such guidelines, it is hoped that 
ERP	 systems	 that	 are	of	 benefit	 to	 all	 stakeholders	and lead to fair pricing and equitable access to health technologies, whilst improving the sustainability of pharmaceutical pricing practices and encouraging innovation, can be developed.
The Implementation of External Reference Pricing within and across Country Borders 36
L O N D O N  S C H O O L  O F  E C O N O M I C S  A N D  P O L I T I C A L  S C I E N C E
6. REFERENCES
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APPENDIX 1Framework of 14 principles for optimal ERP implementation (Sullivan et al. 2017)
Principles1 The objectives of ERP systems should be clear and align with health system objectives2 ERP systems should focus on on-patent products considered for the purposes of coverage, pricing and reimbursement decisions3 Prices developed via ERP do not over-ride HTA conclusions or VBP approaches4 The ERP system should have administrative simplicity and transparency5 Stakeholders should participate in design and review of ERP system6 Stakeholders are able to appeal regulator decisions7 Reference countries should be selected based on similarities in economic status and health system objectives8 International implications of ERP implementation should be considered9 Publicly available ex-factory prices should form the basis of the ERP system10 The mean of prices in reference countries should be used11 ERP system respects patent status of products it covers based on provision of IP that prevail in reference country12 ERP formula should avoid the impact of exchange rate volatility13 Price revisions should be kept to a minimum and should be carried out consistently to avoid the perception of opportunistic behaviour14 ERP-based prices should be aligned with other tools used when negotiating reimbursement
